Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19
| Autor: | Knut Brockow, Ozge Soyer, Annick Barbaud, Marina Atanaskovic-Markovic, Cristobalina Mayorga, María José Torres, A. Romano, Aslı Gelincik, Gülfem Çelik, Inmaculada Doña |
|---|---|
| Přispěvatelé: | Istanbul University, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Ankara University School of Medicine [Turkey], Universidad de Málaga [Málaga] = University of Málaga [Málaga], Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Faculty of Medicine [Hacettepe University], Hacettepe University = Hacettepe Üniversitesi, University of Belgrade [Belgrade], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) |
| Rok vydání: | 2020 |
| Předmět: |
Drug
medicine.medical_specialty [SDV]Life Sciences [q-bio] media_common.quotation_subject desensitization Disease medicine.disease_cause Asymptomatic 03 medical and health sciences 0302 clinical medicine Pandemic medicine drug hypersensitivity reactions Intensive care medicine 030304 developmental biology media_common Coronavirus 0303 health sciences SARS-CoV-2 business.industry COVID-19 medicine.disease 3. Good health Pneumonia medicine.anatomical_structure 030228 respiratory system medicine.symptom Differential diagnosis business Respiratory tract |
| Zdroj: | Allergy Allergy, Wiley, 2020, ⟨10.1111/all.14439⟩ |
| ISSN: | 0105-4538 1398-9995 |
| Popis: | International audience; Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text